Nexalin study shows promise for Alzheimer's treatment with new brain stimulation technology

Nexalin Technology, Inc. announced positive results from a clinical trial of its Deep Intracranial Frequency Stimulation (DIFS) technology for patients with mild Alzheimer’s disease. The study showed significant improvements in memory and cognitive function compared to a control group. The trial involved 46 patients, with those receiving DIFS showing notable gains in cognitive assessments. Functional MRI scans indicated increased neural activity and blood flow in the hippocampus, a key area for memory processing. The treatment was well-tolerated, with only minor side effects reported. Nexalin plans to further explore DIFS technology in upcoming clinical trials to enhance its effectiveness.